Immunomolecular Investigation of Human Papillomavirus Genotypes (16, 18) and P63 Expression in Patients with Malignant and Non-malignant Colorectal Tumors.

Cancer of the colon (colorectal cancer, or CRC) is the third most frequent malignancy in the world and the fourth leading cause of cancer-related death. Recent research has focused on the link between high-risk human papillomavirus (HPV) infections and the onset/development of several different types of cancer in humans. As a result, scientists are now paying more attention to HPV and CRC. In a variety of malignant tumors, P63 is overexpressed. This includes non-Hodgkin lymphoma and breast carcinoma, as well as lung, bladder, and prostate cancers. However, in accordance with the existence of many P63 isoforms in malignant tumors, the actions of P63 in these malignancies remain a source of debate. P63 immunohistochemistry expression in CRC tissues is being investigated as a possible etiological link between high-risk HPV types and CRC. This retrospective study intended to investigate if there was an etiological link between high-risk HPV types and CRC. It has utilized 92 chosen formalin-fixed and paraffin-embedded tissue block samples. The collected samples were divided into 62 blocks of colorectal adenocarcinoma mass tissues and 30 non-malignant colorectal tissues used as a control group. Chromogenic in situ hybridization (CISH) was employed to discover HPV DNA16/18 in colorectal tissues. The overall proportion of positive HPV16/18 DNA- CISH detection in the mass CRC group was 44.4%, whereas HPV16/18 DNA was obtained at 80.0% in the non-malignant control group. The overall proportion of positive P63-ISH detection in the CRC group was also 70.4%, whereas P63 was 73.3% in the non-malignant control group. The link between HPV infection and P63 expression in CRC might point to the importance of these molecules in the progression of CRC.

Tracing Some Salivary Immune Elements in Iraqi SARS-2 Patients.

Saliva is one of the most significant components in maintaining oral homeostasis and symbiosis. It contains antimicrobial proteins and peptides, such as mucins, lactoferrin, lysozyme, lactoperoxidase, Catherine, statins, and antibodies (secretory immunoglobin A [sIgA]). Early defenses against respiratory infections rely heavily on mucosal immunity, especially secretory sIgA, which has several features and functions that make it suitable for mucosal defense. Salivary testing has been utilized to define mucosal immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Lysozyme has muramidase, with antimicrobial activity, and high concentrations in body fluids, such as saliva and tear. This research aimed to offer an update on how saliva components suppress viral infection and sustain health. A total of 50 individuals, including 30 SARS-2 patients and 20 non-infected subjects, in the age range of 32-54 years were enrolled in this study. Saliva specimens were obtained from polymerase chain reaction (PCR)-confirmed coronavirus disease 2019 (COVID-19) patients and non-infected participants. To collect saliva, the subjects were advised to swirl water over their lips three times, and 5.0 ml of saliva was collected. Samples were centrifuged at 800 x g for 10 min. Saliva was diluted at 1:2,000 with 1 × Diluent N. The immunoglobulin A (IgA) titer in saliva was detected. A spectrophotometer was used to measure the solution's change in absorbance at 550 nm. Measurements (salivary IgA and lysozyme) were made after 7, 30, and 60 days of confirmatory PCR COVID-19 test. The mean scores of salivary IgA levels were obtained at 17.85, 15.26, and 10.73 mg/dl in patients and 9.53, 10.33, and 9.21 mg/dl in healthy individuals after 7, 30, and 60 days, respectively. The salivary lysozyme activity levels in SARS-2 patients compared to controls were 9.7, 7.3, and 4.2 mg/dl versus 2.9, 3.4, and 3.77 mg/dl, respectively. The salivary IgA level was significantly higher in patients of a confirmatory test for COVID-19 compared to healthy individuals.

Immunological Evaluation of Individuals Infected with Acinetobacter baumannii.

Acinetobacter baumannii (A. baumannii) is a spherical rod-shaped Gram-negative non-lactose fermenting (Coccobacilli, Aerobic bacteria) bacteria. It is a member of the Moraxellacea family. A. baumannii is a pathogenic, opportunistic organism that infects humans in society and hospitals. In particular, patients with immune system defects are at risk, especially those with burn infections and those hospitalized in intensive care (ICU). It plays a vital role in many illnesses, including septicemia, pneumonia, meningitis, soft tissues, skin infection, endocarditis, and urinary tract infection (UTI). The current study included immunological evaluation of infection with A. baumannii. In the current study, 150 blood samples were obtained as follows: 100 blood samples were collected from infected individuals with A. baumannii admitted to hospitals in Baghdad. Fifty blood samples were obtained from healthy individuals and considered as the control. 10 ml of blood samples were collected from the venous blood of the participants. A. baumannii was collected and isolated from infected patients and diagnosed by traditional methods, using different culture media (MacConkey agar, blood agar, and Chromogenetic agar) and by biochemical assays, then the bacteria diagnosis was confirmed using the VITEK 2 ID-GN cards. Microscopic examination and culture diagnosis of bacteria were conducted, and the diagnosis was confirmed by complete biochemical examinations using VITEK2 Compact System. Assessments included the serum level of IL-17A and TNF-α for hospitalized patients infected with A. baumannii. The study recorded a significant increase in the serum level of IL-17A for patients infected with A. baumannii (479.83±26.21 pg/ml) compared to control subjects (69.32±4.53 pg/ml). The recorded data showed a significant increase in the serum level of TNF-α for patients infected with A. baumannii (98.05±28.89 pg/ml) compared to control (1.40±25.12 pg/ml).